Nuray Tezcan

Nuray Tezcan

Auto-generated profile, based on publicly available information

Nuray Tezcan

Memorial Sloan Kettering Cancer Center 2 Department of Pathology, and Laboratory Medicine New York, New York

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
WPWungki Park
Wungki Park
SUShigeaki Umeda
Shigeaki Umeda
MHMarc Hilmi
Marc Hilmi
COCatherine O’COnnor
Catherine O’COnnor
RSRoshan Sharma
Roshan Sharma
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
Pancreatic cancer (PC) is broadly resistant to immune checkpoint blockade, although a subset of homologous recombination-deficient (HRD) tumors exhibits durable immune engagement. The genomic features that distinguish these immune-responsive tumors from immune-inert HRD tumors remain poorly understood. Here we identify a microhomology-mediated end joining (MMEJ) repair scar, the MMEJ Deletion Footprint (MDF), as a genomic readout of POLQ-associated error-prone repair that enriches for frameshift indels. Across the multi-omic discovery cohort integrating tumor genomics, single-nucleus transcriptomics and spatial immune profiling, MDF-high HRD PC exhibited increased frameshift-indel-derived neoantigens and interferon programs. MDF was further associated with remodeling of the myeloid compartment toward MHC II-high dendritic cell-like antigen-presenting macrophage states and the immune synapse architecture marked by increased spatial interaction between APC-like macrophages and cytotoxic CD8 + T cells. These tissue-level features aligned with a functional trajectory shift of CD8 + T cells, consistent with effective anti-tumor immunity and was associated with favorable clinical outcomes of patients. Together, our findings position MMEJ-linked repair scarring as actionable biology that connects an HRD genotype to immune organization and suggests rational immunotherapy combinations that may enhance antigen presentation and myeloid activation to extend durable benefit in HRD-lineage cancers.

24 September 2025 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
NTNuray Tezcan
Nuray Tezcan
RERohat Esmer
Rohat Esmer
GCGulbanu Canbaloglu
Gulbanu Canbaloglu
GBGokhan Baysoy
Gokhan Baysoy
PKPınar Korkmaz
Pınar Korkmaz
BSBurcu Saka
Burcu Saka

29 March 2026 in Histopathology
Verified
Journal Article
Closed access
PDF file
OYOsman Yilmaz
Osman Yilmaz
BABerk Kaan Aktaş
Berk Kaan Aktaş
NTNuray Tezcan
Nuray Tezcan
VDVikram Deshpande
Vikram Deshpande
VAVolkan Adsay
Volkan Adsay
MVMonika Vyas
Monika Vyas


8 July 2025 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NTNuray Tezcan
Nuray Tezcan
LGLal Sude Gucer
Lal Sude Gucer
AAAslı Aydın
Aslı Aydın
CMCisel Aydin Mericoz
Cisel Aydin Mericoz
PBPınar Bulutay
Pınar Bulutay
IKIbrahim Kulac
Ibrahim Kulac
Background: PD-L1 expression guides immunotherapy decisions in non small cell lung cancer (NSCLC), yet sample type can impact assessment accuracy. This study aimed to compare PD-L1 expression between small (biopsies, cell blocks) and large (resection) NSCLC samples, assess interobserver variability, and examine whether PD-L1 scoring trends remained stable over a multi-year period. Methods: A retrospective analysis was conducted on 494 NSCLC patients tested for PD-L1 (Ventana SP263) between 2018 and 2022. Sample type, tumor subtype, PD-L1 tumor proportion score (TPS), and reporting pathologist were recorded. Interobserver variability was analyzed based on routine diagnostic reports from different pathologists evaluating non-overlapping patient cohorts. Additionally, a subset of 43 patients had matched cell block and resection specimens collected from the same tumor, allowing direct comparison between preparations. Results: Among the 494 NSCLC specimens, 152 were large and 342 were small samples. TPS results showed 112 samples (22%) with TPS ≥ 50%, 163 (34%) with TPS 1%–49%, and 219 (44%) with TPS < 1%. No significant differences in TPS categories were observed between cell blocks and tissue samples (p = 0.176) or between small and large samples (p = 0.326). TPS distributions across different pathologists (p = 0.260) and years (p = 0.250) remained consistent. In the matched 43 specimens, TPS concordance between cell block and resection was high (κ = 0.892). Conclusion: Small biopsies and cell blocks provide reliable PD-L1 results comparable to resection specimens, supporting their use for PD-L1 testing in clinical settings to enhance timely immunotherapy access for NSCLC patients.

14 October 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
ADAruj Dhyani
Aruj Dhyani
NTNuray Tezcan
Nuray Tezcan
JCJoanne F. Chou
Joanne F. Chou
ZTZeynep Tarcan
Zeynep Tarcan
RTRohit Thummalapalli
Rohit Thummalapalli
JHJames J Harding
James J Harding
Purpose: Data on antibody–drug conjugates (ADC) target expression prevalence, intertumoral heterogeneity, and genomic concordance, and its effect on clinical outcomes is limited in biliary tract cancers. Experimental Design: Resected primary biliary tract cancer specimens and, when available, matched metastatic samples were assembled into tissue microarrays (TMA) and tested for CLAUDIN18.2 (CLDN18.2), c-MET, Nectin-4, TROP2, and HER2 expression by immunohistochemistry (IHC). A subset underwent targeted next-generation sequencing using MSK-IMPACT (NCT01775072). Exploratory associations of target expression with clinicopathologic parameters, genomic alterations, recurrence-free survival (RFS), and overall survival (OS) were evaluated. Results: Sixty-five patients with resected biliary tract cancer and 18 paired metastatic sites were identified—43% extrahepatic cholangiocarcinoma, 40% intrahepatic cholangiocarcinoma, and 17% gallbladder cancer. All evaluated target antigens were expressed; percent positivity and H-score ≥200 were 83% and 26% for TROP2, 75% and 26% for c-MET, 66% and 35% for Nectin-4, and 46% and 7.7% for CLDN18.2, respectively. HER2 overexpression occurred in 3.1% of tumors. Overall agreement among paired primary and metastatic samples on calling either positive or negative ranged from 43% to 75%, with the highest observed for HER2 {75%; κ = 0.29 [95% confidence interval (CI), −0.32 to 0.91]} and TROP2 (71%; κ not available) and lowest for c-MET, CLDN18.2, and Nectin-4. Frequently altered genes included TP53 (36%), SMAD4 (27%), and ELF3 (21%). We observed no significant association between target antigen expression and genomics, RFS, or OS. Conclusions: Biliary tract cancer displays frequent but heterogeneous expression of multiple ADC targets. These hypothesis-generating findings suggest inherent complexity of target protein quantification, target threshold determination, and target sampling discordance. Future studies will be required to refine our understanding of the utility of ADCs in biliary tract cancer.